Catching pancreatic cancer early: the promise of affordable biomarkers to regularly screen high-risk individuals
Translational Gastroenterology and Hepatology · 2026-07 · 11 · 78-78
DOI: 10.21037/tgh-2026-0064 ↗Kurz gefasst
Editorial in der Zeitschrift Translational Gastroenterology and Hepatology, 2026-07. Verfasst von Geou-Yarh Liou. Beteiligte Einrichtung: Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, GA, USA. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIMHD NIH HHS.
Abstract (Originalsprache)
. Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study. Lancet Gastroenterol Hepatol 2025;10:634-47
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, GA, USA.
- Department of Biological Sciences, Clark Atlanta University, Atlanta, GA, USA.
ORCID-Profile: Geou-Yarh Liou
Förderung
- NIGMS NIH HHS
- NIMHD NIH HHS
Zitieren
APA
Liou, G. Y. (2026). Catching pancreatic cancer early: the promise of affordable biomarkers to regularly screen high-risk individuals. Translational Gastroenterology and Hepatology, 11, 78-78. https://doi.org/10.21037/tgh-2026-0064
Vancouver
Liou GY. Catching pancreatic cancer early: the promise of affordable biomarkers to regularly screen high-risk individuals. Translational Gastroenterology and Hepatology. 2026;11:78-78. doi:10.21037/tgh-2026-0064
BibTeX
@article{Liou2026,
author = {Liou, Geou-Yarh},
title = {Catching pancreatic cancer early: the promise of affordable biomarkers to regularly screen high-risk individuals},
journal = {Translational Gastroenterology and Hepatology},
year = {2026},
volume = {11},
pages = {78--78},
doi = {10.21037/tgh-2026-0064}
}
EUVIMED